

## Bangladesh Support for Measles-Rubella Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Bangladesh			
<b>2. Grant number:</b> 17-BGD-09a-X / 17-BGD-18a-A / 18-BGD-18e-A / 12-BGD-08a-Y			
<b>3. Date of Decision Letter:</b> 21 December 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 24 June 2013			
<b>5. Programme title:</b> New vaccine support (NVS), Measles-Rubella catch-up campaign and Measles-Rubella routine 1st and 2nd dose			
<b>6. Vaccine type:</b> Measles-Rubella			
<b>7. Requested product presentation and formulation of vaccine:</b> Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
<b>8. Programme duration<sup>1</sup>:</b> 2012 - 2018			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	2012-2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	8,450,103 <sup>3</sup>	1,252,759	9,702,862
 <b>Fragility, Emergencies and Refugees Policy (Gavi supported)</b>			
	2017	2018	Total <sup>4</sup>
Programme Budget (US\$)	259,000	80,000	339,000

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

**10. Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)<sup>5</sup>

Type of supplies to be purchased with Gavi funds in each year	2012-2016	2017
Number of Measles-Rubella vaccines doses		4,431,400
Annual Amounts (US\$)	8,450,103 <sup>6</sup>	1,252,759

**Fragility, Emergencies and Refugees Policy (Gavi supported)**

Type of supplies to be purchased with Gavi funds in each year (Campaign)	2017	2018
Number of Measles-Rubella vaccines doses	404,100	0
Annual Amounts (US\$)	259,000	0

Type of supplies to be purchased with Gavi funds in each year (Routine)	2017	2018
Number of Measles-Rubella vaccines doses	0	124,300
Annual Amounts (US\$)	0	80,000

**11. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**12. Self-procurement:** Not applicable

<sup>5</sup> This is the amount that Gavi has approved.

<sup>6</sup> This is the consolidated amount for all previously approved years.

**13. Co-financing obligations for routine immunisation for refugees:** Reference code: **18-BGD-18e-A-C**

According to the co-financing policy, Bangladesh falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

**Fragility, Emergencies and Refugees Policy**

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	98,200
Number of AD syringes	73,300
Number of re-constitution syringes	10,800
Number of safety boxes	950
Value of vaccine doses (US\$)	60,637
Total co-financing payments (US\$) (including freight)	67,000
Minimum number of doses to be financed from domestic resources	48,604
Minimum amount to be financed from domestic resources (US\$)	30,038

**14. Co-financing obligations for campaign:** Not applicable

**15. Vaccine introduction grant (in US\$):** A VIG in the amount of US\$1,195,500 was previously disbursed on 04/04/2012.

**16. Operational support for campaigns:** Not applicable

**17. Additional reporting requirements:**

Bangladesh shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**18. Financial clarifications:** Not applicable

**19. Other conditions:** As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,

*Hind A. Khatib*

**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
21 December 2017